Welcome to our dedicated page for COOPER COMPANIES SEC filings (Ticker: COO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on COOPER COMPANIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into COOPER COMPANIES's regulatory disclosures and financial reporting.
Cooper Companies director Maria Rivas reported routine equity compensation changes. She exercised restricted stock units into 3,322 shares of common stock on April 1, 2026, and now holds 3,322 shares directly. She also received a new grant of 3,779 restricted stock units scheduled to vest on April 1, 2027. In addition, 11,141 common shares are held indirectly through The Maria Rivas Trust Dated June 24, 2013, where she serves as sole trustee.
Cooper Companies director Colleen Jay reported equity compensation activity involving restricted stock units and common shares. On April 1, 2026, 3,322 restricted stock units were exercised and converted into 3,322 shares of common stock. On the same date, Jay also received a new grant of 4,157 restricted stock units, which may vest or be forfeited and has no expiration date. Following these transactions, Jay directly owned 39,907 shares of common stock and held 4,157 restricted stock units.
Cooper Companies director Barbara Carbone reported routine equity compensation activity. On April 1, 2026, she exercised 3,050 Restricted Stock Units, converting them into 3,050 shares of Common Stock at a stated price of $0.00 per share, reflecting non-cash vesting rather than a market purchase.
On the same date, she also received a new grant of 3,779 Restricted Stock Units, each representing a right to acquire one share of Common Stock. The award has no expiration date; the units will either vest or be forfeited over time. Following these transactions, she directly holds 3,050 shares of Common Stock and 3,779 Restricted Stock Units.
Rosebrough Walter M Jr reported acquisition or exercise transactions in this Form 4 filing.
COOPER COMPANIES, INC. director Walter M. Rosebrough Jr received a grant of 3,779 Restricted Stock Units on April 1, 2026 as equity compensation. Each unit represents one share of common stock.
The RSUs are scheduled to vest on April 1, 2027 and have no expiration date; they will either vest or be forfeited. Following this award, he holds 3,779 RSUs directly, and there were no open-market purchases or sales in this filing.
COOPER COMPANIES, INC. director Teresa S. Madden reported routine equity compensation activity involving restricted stock units and common shares. On April 1, 2026, she exercised 3,322 restricted stock units into 3,322 shares of common stock at $0.00 per share, increasing her direct common stock holdings to 15,679 shares.
On the same date, she received a new grant of 3,779 restricted stock units, each representing one share of common stock, scheduled to vest on April 1, 2027. A related footnote explains that this award has no expiration date and that the units will either vest or be forfeited, underscoring their service-based nature rather than being a market transaction.
Cooper Companies director Cynthia L. Lucchese reported compensation-related equity activity. On April 1, 2026, she exercised 3,322 Restricted Stock Units, acquiring the same number of common shares at a stated price of $0.00 per share. She also received a new grant of 3,779 Restricted Stock Units, which are scheduled to vest on April 1, 2027. After these transactions, she holds 12,767 shares of Cooper Companies common stock directly. A footnote explains the RSU award has no expiration date and that units will either vest or be forfeited.
Cooper Companies director Lawrence Erik Kurzius reported equity compensation activity involving restricted stock units and common stock. He exercised 3,322 Restricted Stock Units into 3,322 shares of Common Stock at a stated price of $0.00 per share, converting a derivative award into stock ownership.
He also received a new grant of 3,779 Restricted Stock Units, which have no expiration date and will either vest or be forfeited according to the award terms. Following these transactions, he directly owns 11,099 shares of Common Stock and holds 3,779 Restricted Stock Units, reflecting routine compensation-related acquisitions rather than open-market buying or selling.
Cooper Companies, Inc. ownership filing amended: The Vanguard Group reports 0 shares beneficially owned of Common Stock, representing 0%. The amendment explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, with disaggregated reporting by subsidiaries. filing signed March 26, 2026.
The Cooper Companies reported higher quarterly sales and profit for the three months ended January 31, 2026. Net sales rose to $1,024.1 million from $964.7 million, driven mainly by growth in CooperVision contact lenses and steady gains in CooperSurgical office, surgical, and fertility products.
Net income increased to $130.8 million from $104.3 million, with diluted earnings per share up to $0.66 from $0.52. CooperVision delivered operating income of $210.2 million and CooperSurgical $26.8 million, as overall operating margin improved to 21%. Operating cash flow strengthened to $260.9 million, supporting $102.2 million of capital spending and $92.5 million of share repurchases.
The company ended the quarter with total assets of $12,424.2 million and total debt of $2,499.7 million. Subsequent amendments extended the maturity of $950.0 million of term loans to 2031. Cooper also disclosed a U.K. payroll tax dispute with a reasonably possible loss range of £0–£71.7 million, plus interest, for which no liability has been recorded.
CooperCompanies reported a solid fiscal first quarter 2026, with revenue of $1.024 billion, up 6% from a year earlier and 3% organically. Growth was led by CooperVision, where revenue rose 8% to $695.1 million, while CooperSurgical revenue increased 3% to $329.0 million.
GAAP diluted EPS grew to $0.66, up 27%, and non-GAAP diluted EPS rose to $1.10, up 20%, as operating margin improved to 21% on a GAAP basis and 27% on a non-GAAP basis. Free cash flow was $158.7 million, supporting $92.5 million of share repurchases. The company raised its fiscal 2026 outlook, guiding total revenue to $4.306–$4.346 billion, non-GAAP EPS to $4.58–$4.66, and free cash flow to $600–$625 million.